Results 181 to 190 of about 420,147 (288)

Decoding the Pathophysiology of Autoimmune Diseases—Mechanism, Triggers, and Nanotherapeutics: A Review

Advanced NanoBiomed Research, EarlyView.
This review highlights how autoimmune diseases arise from intertwined immunological, genetic, and environmental factors, emphasizing gut microbiota dysbiosis as a pivotal driver. It outlines emerging nanotechnology‐based strategies—such as liposomes, hydrogels, and polymeric nanoparticles—that enhance targeted drug delivery, minimize systemic toxicity,
Md. Meraj Ansari, Yunhui Min, Eun‐Ju Ko, Doyoung Kwon, Rehan Khan, Young‐Ok Son   +5 more
wiley   +1 more source

Circle of Security-Parenting and Parent-Child Interaction Therapy-Toddler: A Qualitative Exploration of Parents' Perspectives. [PDF]

Scand J Psychol
Kohlhoff J, Cibralic S, Wallace N, Morgan S, Lennie L, Rabbetts L.   +5 more
europepmc   +1 more source

Internet parent-child interaction therapy (I-PCIT) in medically ill child: A case report. [PDF]

Medicine (Baltimore), 2021
Melo V, Zaccariello M, Girard E, Croarkin P, Romanowicz M.   +4 more
europepmc   +1 more source

Mechanistic Insights Into Photocatalytic Materials for Toxic Pollutants: Environmental Remediation of Personal Care Products

Asia-Pacific Journal of Chemical Engineering, EarlyView.
ABSTRACT Photocatalytic materials have emerged as promising solutions for environmental applications due to their ability to degrade organic pollutants under sunlight or artificial light. In this review, recent progress on the photocatalytic materials used for the degradation of pharmaceutical personal care products (PPCPs) in environmental ...
Urvashi Sen, Gunjan Chauhan, Surbhi Soni, Monika Vats, Anand Kumar, Indra Bahadur   +5 more
wiley   +1 more source

Effect of Time to Start of Biologic Therapy on Treatment Response in Childhood Arthritis: Results From the UCAN CAN‐DU Cohort

Arthritis &Rheumatology, EarlyView.
Objective To estimate the effect of time from symptom onset to start of biologic treatment on achieving inactive arthritis within six months in a cohort of patients with juvenile idiopathic arthritis (JIA). Methods The international UCAN CAN‐DU study prospectively enrolled patients with JIA across Canada and the Netherlands.
Jelleke B. de Jonge, Sytze de Roock, Dieneke Schonenberg‐Meinema, J. Merlijn van den Berg, Deborah A. Marshall, Sebastiaan J. Vastert, Rae S. M. Yeung, Joost F. Swart, Susanne M. Benseler, on behalf of the UCAN CAN‐DU and UCAN CURE consortia, Adam Huber, Bianca Lang, Chelsea DeCoste, Elizabeth Stringer, Suzanne Ramsey, Alan Rosenberg, Kate Neufeld, Mehul Jariwala, Tristan Kerr, Alexander Mosoiu, Alisa Rachlis, Amy Xu, Arthur Cheng, Brenleigh Jebb, Brian Feldman, Bruno Pereira, Deborah Levy, Dilan Dissanayake, Elizaveta Limenis, Evelyn Rozenblyum, Harper Cheng, Jennifer Ji Young Lee, Lynn Spiegel, Rayfel Schneider, Ronald Laxer, Ruud Verstegen, Shirley Tse, Trang Duong, Andrea Human, David Cabral, Herman Tam, Jaime Guzman, Kim Morishita, Kristin Houghton, Lori Tucker, Mercedes Chan, Ross Petty, Tommy Gerschman, Annet van Royen‐Kerkhof, Berent Prakken, Erika Van Nieuwenhove, Marc Jansen, Nico Wulffraat, Ciarán Duffy, Nadia Luca, Roman Jurencak, Tala El Tal, Claire LeBlanc, Gaëlle Chédeville, Piya Lahiry, Rosie Scuccimarri, Sarah Campillo, Clare Hutchinson, Daniah Basodan, Dax G. Rumsey, Hon Yan Ng, Jeanine McColl, Lillian Lim, Tara McGrath, Danielle Brinkman, Petra Hissink Muller, Elizabeth Legger, Wineke Armbrust, Ellen Schatorje, Esther Hoppenreijs, Elodie Boudes, Gillian Currie, Heinrike Schmeling, Muhammed Dhalla, Nicole Johnson, Paivi Miettunen, Ravneet Sran, Rebeka Stevenson, Erkan Demirkaya, Jonathan Park, Roberta Berard, Giske Biesbroek, Mariken Gruppen, Gordon Soon, Joseph Cafazzo, Liane Heale, Michelle Batthish, Tania Cellucci, Lily Lim, Maarten IJzerman, Marinka Twilt, Marleen Verkaaik, Philomine van Pelt, Sylvia Kamphuis, Michelle Kip, Nickolas Blanchette, Paul Dancey, Regina de Geus   +102 more
wiley   +1 more source

Tofacitinib for the Treatment of Juvenile Idiopathic Arthritis: Patient‐Reported Outcomes in a Phase 3, Randomized, Double‐Blind, Placebo‐Controlled Withdrawal Trial

Arthritis &Rheumatology, EarlyView.
Objective Juvenile idiopathic arthritis (JIA) is associated with impaired overall health‐related quality of life (HRQoL). We evaluated the impact of tofacitinib on patient‐reported outcomes (PROs) in patients with JIA. Methods This was a post hoc analysis of a phase 3, randomized, double‐blind, placebo‐controlled withdrawal trial (NCT02592434) in ...
Hermine I. Brunner, Ekaterina Alexeeva, Marcia Bandeira, Ruy Carrasco, Jeffrey Chaitow, Peter Chiraseveenuprapund, Tracy V. Ting, Muferet Erguven, Beth Gottlieb, Sheila Knupp Oliveira, Pooja N. Patel, Seza Ozen, Claudia Saad Magalhaes, Inmaculada Calvo Penadés, David Gruben, Rebecca Germino, Holly B. Posner, Lori Stockert, Alberto Martini, Daniel J. Lovell, Nicolino Ruperto, for the Paediatric Rheumatology International Trials Organisation (PRINTO) and Pediatric Rheumatology Collaborative Study Group (PRCSG)   +21 more
wiley   +1 more source

A Statewide Randomized Controlled Trial to Compare Three Models for Implementing Parent Child Interaction Therapy. [PDF]

J Clin Child Adolesc Psychol, 2023
Herschell AD, Kolko DJ, Scudder AT, Taber-Thomas SM, Schaffner KF, Hart JA, Mrozowski SJ, Hiegel SA, Iyengar S, Metzger A, Jackson CB.   +10 more
europepmc   +1 more source

OGFRL1 deficiency causes CRMO via pathological osteoclastogenesis, with therapeutic response to TNF inhibitor

Arthritis &Rheumatology, Accepted Article.
Objectives To verify the pathogenesis of the OGFRL1 loss‐of‐function variant (c.30del, p. F10Ffs*110) identified in a CRMO patient and investigate the underlying mechanism. Methods Whole exome sequencing and Sanger sequencing were performed to identify and confirm the variant.
Wen Xiong, Yusha Wang, Tingyan He, Jinjian Fu, Ying Luo, Jinbo Wang, Jun Wang, Xiaomin Yu, Qing Zhou, Jun Yang   +9 more
wiley   +1 more source

The Added Value of Parents Practicing in Virtual Reality to Illustrate the Use of Innovative Methods in Parent-Child Interaction Therapy: Single-Case Experimental Design. [PDF]

JMIR Pediatr Parent
Scherpbier ICA, Abrahamse ME, Bouwmeester S, Belleman RG, Popma A, Lindauer RJL.   +5 more
europepmc   +1 more source

Home-Based Parent-Child Interaction Therapy to Prevent Child Maltreatment: A Randomized Controlled Trial. [PDF]

Int J Environ Res Public Health, 2021
Abrahamse ME, Tsang VMW, Lindauer RJL.
europepmc   +1 more source